Review Article

Carcinogenic Chemicals and Drugs: Unravelling the Complexities of Cancer Induction

Abstract

Cancer initiation is a multifaceted process influenced by various carcinogens and pharmaceuticals, significantly contributing to disease onset and progression. The interplay between genetic anomalies and environmental factors precipitates uncontrolled cell growth and tumor formation. Carcinogenic substances, spanning industrial compounds to medications, disrupt the delicate biological equilibrium, expediting genetic mutations and the development of tumors. This review investigates the mechanisms involved in cancer onset, categorizing contributors into three groups: carcinogenic agents, molecular regulators, and chemo-preventive substances. Carcinogens like 12-O-tetradecanoylphorbol-13-acetate (TPA), arsenic, topoisomerase inhibitors, alkylating chemicals, radiation, hormones, and hypoxia are scrutinized for their modes of action. Conversely, anti-cancer medications such as retinoids and kinase inhibitors are highlighted for their potential in cancer management. Meanwhile, signaling molecules like TGF and TNF play complex roles, switching between tumor suppression and promotion. While E2F, a transcription factor family regulating the cell cycle, and Bcl-2, a protein modulating cell death, are involved in cancer development and treatment, they are not typically primary chemo-preventive agents like Barbital, Genistein, or Aspirin, which are specifically studied for their preventive effects against cancer. This review aims to enhance understanding of cancer causation, providing detailed insights for refining prevention and treatment strategies.

Graphical Abstract



Keywords: Carcinogens, carcinogenesis, chemical carcinogens, cancer risk, environmental factors, targeted therapies, mutagenesis, regulatory oversight.

Introduction

Cancer, a complicated and severe disease spectrum, develops as a result of the intricate interplay between genetic alterations and extrinsic influences [1], [2]. It is characterized by uncontrolled cellular growth and division, leading to the formation of tumors, which are abnormal tissue masses [3]. These tumors can penetrate and damage nearby tissues and, in more worrying situations, spread via the complex process of metastasis to distant anatomical regions [4], [5]. While genetic variations lay the groundwork for cancer development,

environmental influences also significantly contribute to this malignancy [6]. Carcinogenic substances and certain drugs have emerged as potent factors in increasing susceptibility to cancer among these ecological elements [7]. These compounds can increase cancer risk by directly damaging DNA or disrupting essential cellular processes [8]. As our understanding of the numerous processes underlying the development of cancer deepens, there is an increasing need to carefully examine the diverse properties of these agents and understand their intricate relationship with human health [9].

Cancer is primarily driven by uncontrolled cell growth arising from a sequence of genetic mutations within a cell's DNA [10]. These mutations disrupt the regulation of cell cycle checkpoints, apoptosis (programmed cell death), and DNA repair mechanisms. Consequently, the affected cells gain a selective advantage for unrestricted proliferation, leading to the formation of abnormal cell populations that eventually form tumors [11], [12]. While genetic mutations can occur naturally due to errors in DNA replication, exposure to external factors can significantly accelerate this process [13]. Carcinogenic chemicals and medicinal compounds play a substantial role among these external agents, capable of hastening genetic changes. These agents encompass a broad spectrum of chemicals, ranging from industrial contaminants to medicinal compounds, all of which possess the capability to disrupt the delicate balance of biological systems [14]. Some of these chemicals cause direct DNA damage, resulting in structural changes that differ from the normal genetic code [15]. Others disrupt critical cellular pathways, impairing the cell's ability to respond correctly to environmental signals and maintain genetic integrity. Exposure to such substances triggers a hazardous transformation in cells, creating an environment conducive to the initiation of cancerous processes [16], [17].

Cancer initiation is a broad and profound topic of scientific and medical investigation characterised by the complicated interplay of numerous variables. The functions of carcinogenic substances and anti-cancer medications are pivotal components, with the capacity to either cause the disease's beginning or act as indispensable aids in its management [18-20]. This study seeks to comprehensively investigate the intricate mechanisms underlying cancer induction by systematically analyzing the roles of carcinogenic chemicals, anti-cancer treatments, and chemo-preventive medicines [21-24]. A complex issue driven by multiple interrelated variables is the rise in cancer incidence and mortality on a global scale. The concurrent trends of population aging and changes in the prevalence and distribution of key cancer risk factors linked to socioeconomic development are all responsible for this increasing

burden. Cancer has become a major cause of death as the world's population ages and grows larger [25]. This is partly because cancer mortality rates are significantly lower globally than those of other diseases like stroke and coronary heart disease [26][27]. The correlation between cancer's prevalence as a determinant of premature mortality and the diverse spectrum of social and economic development levels evident across nations underscores the intricate interplay of multifaceted factors contributing to the escalating global impact of cancer on public health [28].

Cell death is a fundamental process in both normal physiology and disease states, being a universal fate for all living organisms. It is often categorized into regulated cell death (RCD) and accidental cell death (ACD). ACD occurs due to unexpected external stimuli or injuries, while RCD is orchestrated by specific signaling pathways involving effector molecules [25]. The concept of RCD was introduced through the understanding of apoptosis, first described by Kerr and colleagues in the 1970s, which highlighted its involvement in various physiological and pathological processes [29]. Subsequent research expanded the understanding of RCD beyond apoptosis, identifying several non-apoptotic forms such as lysosome-dependent cell death, NETotic cell death, cuprotosis, ferroptosis, pyroptosis, entosis, parthanatos, alkaliptosis, oxeiptosis, and parthanatosis. Studies on the dysregulation of these RCD pathways are rapidly advancing, particularly about various human disorders, notably cancer. Dysregulation of physiological RCD or inadequate control of abnormal cell proliferation is closely linked to an increased risk of developing malignant tumors [30].

The wide array of carcinogens capable of inducing cancer presents a perplexing aspect of the disease's origin. These include potent tumor promoters like TPA, the subtle yet long-lasting effects of arsenic exposure, and the DNA-damaging properties of alkylating agents [31]. Extensive research has been conducted to understand the mechanisms through which these chemicals initiate and promote cancer [32]. Their diverse impacts on cellular functions and molecular pathways contribute to this complexity, highlighting the intricate nature of the disease. Simultaneously, the field of anti-cancer pharmacology offers a range of medications, such as COX-2 inhibitors, HDAC inhibitors, and kinase inhibitors, aimed at halting cancer progression. This review not only emphasizes the therapeutic potential of these medications and the importance of maximizing their clinical utility but also explores the mechanisms by which they inhibit tumor growth and metastasis, while also discussing potential avenues for the development of new cancer-fighting drugs. In conjunction with efforts to combat cancer, increasing research emphasizes the importance of cancer prevention. Chemo-preventive agents

such as retinoids, barbital, genistein, and aspirin, along with the regulation of crucial cellular pathways like TGF, TNF, E2F, and Bcl-2, offer a novel approach to reducing cancer risk by halting the progression of precancerous cells and mitigating the effects of carcinogenic agents, showcasing the potential for targeted cancer prevention [33-38].

2. Types of Carcinogens

The term "carcinogens" encompasses a wide range of compounds that can be classified into distinct groups, including chemical carcinogens, physical carcinogens, biological carcinogens, and pharmaceuticals with potential carcinogenic properties [39]. Exposure to radiation, such as X-rays and gamma rays, can elevate the risk of cancer by generating reactive oxygen species (ROS) and free radicals in our cells. These substances can damage lipids, proteins, and DNA, potentially leading to genetic alterations [40]. Prolonged exposure to ionizing radiation from sources like medical procedures or the environment can heighten the risk of cancer, particularly in tissues sensitive to radiation [40]. Certain substances commonly found in tobacco smoke, industrial pollutants, and some dietary additives can also induce cancer [41]. This occurs when otherwise harmless molecules undergo metabolic processes in our bodies, transforming into highly reactive and cancer-causing metabolites. These metabolites can bind to crucial biological components such as DNA, forming adducts and causing mutations. Viruses contribute to cancer development through the production of viral oncoproteins or by integrating their genetic material into our cells. This alteration disrupts normal cell regulation, promoting uncontrolled cell growth and division. Examples of such viruses include the hepatitis B virus (HBV), linked to liver cancer, and the human papillomavirus (HPV), associated with cervical cancer [42]. Preventing virally induced malignancies requires understanding and addressing viral infections. Some bacteria can cause inflammation in the human body by releasing proinflammatory chemokines and cytokines [42][43]. Chronic inflammation generates reactive molecules that can damage DNA and destabilize genetic material, creating an environment conducive to cancer formation. Reducing the risk of cancer and improving overall health requires awareness of the substances to which we are exposed, including radiation, chemicals, viruses, and bacteria, as illustrated in **Fig. 1**.



Fig. 1. Highlights the complex process of carcinogenesis by highlighting the four primary causes of cancer: radiation, chemicals, viruses, and bacteria. Ionizing and non-ionizing radiation both produce free radicals and ROS, which cause DNA damage. Chemical carcinogens create carcinogenic metabolites, which can change oncogenes and promote unchecked cell proliferation while also causing DNA damage and mutations. Viral oncoproteins and oncogenic genetic elements enable viruses to interact with cellular proteins to avoid immune surveillance, cause inflammation, and ultimately cause DNA damage. As a result of bacterial infections, proinflammatory chemokines and cytokines are released, causing long-lasting inflammation and DNA damage brought on by ROS. A crucial stage towards the emergence of cancer, DNA damage, and mutations are the common outcome in each instance. This graphic is a helpful visual tool that explains the complex network of connections that underlies the development of cancer as a result of many etiological variables.

Chemical carcinogens directly target DNA structures, initiating mutagenesis processes. Examples include polycyclic aromatic hydrocarbons (PAHs) in cigarette smoke and aflatoxins in certain food products. Physical agents, such as ionizing and UV light, damage DNA through different mechanistic processes. The genomes of host cells can be invaded by biological agents, most notably certain viruses including HPV and HBV, which can lead to uncontrolled cell growth [44]. In addition, therapeutic medications, including specific chemotherapeutic agents and immunosuppressive compounds, can inadvertently cause carcinogenesis by disrupting processes that regulate the cell cycle and DNA repair.

A wide range of carcinogenic substances, each with unique processes and consequences, are involved in carcinogenesis, the intricate process that results in the development of cancer [45], [46]. TPA, a strong tumor promoter, is essential for initiating a number of cellular processes that lead to the development of cancer [47]. Arsenic, a natural element and environmental pollutant, has been linked to several types of cancer and has subtle, long-term effects on cellular DNA integrity [48]. Topoisomerase inhibitors hinder DNA replication and repair processes,

leading to the accumulation of genetic mutations. Alkylating chemicals, known for their ability to damage DNA, can both initiate and promote cancer [49]. Ionizing radiation, another known carcinogen can induce chromosomal changes and DNA damage [50]. Hormones can accelerate hormone-dependent cancers like breast and prostate cancer, particularly when hormonal balance is disrupted [51]. Moreover, hypoxia, or reduced oxygen supply, can alter cellular signaling pathways to promote cancer development and spread [52]. These various carcinogenic factors highlight the complexity of cancer induction and emphasize how crucial it is to comprehend how each one contributes differently to oncogenesis.

Table 1. Succinctly summarizes carcinogenic compounds, their target tissues, mechanisms of action, and associated agents and substances. It serves as a valuable reference for comprehending how these substances impact specific organs or systems, their carcinogenic processes, and other factors influencing their effects.

Carcinogenic Chemicals	Target Tissue	Potential Mode of Action	Associated Agent/Substance	Reference
Formaldehyde	Nasal Cavity	Induces DNA damage, promotes nasal cancer	Occupational exposure (e.g., certain industries)	[53]
Benzene	Bone Marrow, Blood	Disrupts hematopoiesis, promotes leukemia	Occupational exposure (e.g., petrochemical industry)	[54]
Arsenic	Skin, Lung, Bladder	Promotes oxidative stress, disrupts DNA repair	Contaminated drinking water, certain industrial exposures	[55]
Vinyl Chloride	Liver, Lungs	Metabolites cause DNA damage and protein dysfunction	Occupational exposure (e.g., plastics manufacturing)	[56]
Chromium (VI)	Lung, Nasal Cavity	Generates ROS, DNA damage	Occupational exposure (e.g., in metalworking)	[57]
Nickel Compounds	Lung, Nasal Cavity	Impair DNA repair, cause oxidative stress	Occupational exposure (e.g., nickel refining)	[58]
1,3-Butadiene	Blood, Lymphatic	Forms DNA adducts, disrupts cell cycle control	Occupational exposure (e.g., rubber production)	[59]

Acrylamide	Nervous System, Liver	Forms DNA adducts, induces mutations in nerve cells	Present in certain foods cooked at high temperatures	[60]
Polycyclic Aromatic Hydrocarbons	Various Tissues	Activate carcinogen-metabolizing enzymes, DNA damage	Found in tobacco smoke, air pollution, and grilled meat	[61]

Arsenic is one of the well-known carcinogens, a poisonous substance presents in the environment that significantly increases the risk of cancer in people. Long-term exposure to arsenic has been associated with the emergence of various cancer forms, including skin, lung, and bladder cancer [62]. This exposure can occur through polluted drinking water or industrial settings [63]. DNA damage and changes in gene expression are two of the processes through which arsenic causes cancer [64]. DNA damage brought on by arsenic can result in mutations that start and fuel the development of malignant cells from healthy ones. Additionally, exposure to arsenic can skew the delicate balance of gene control, which promotes the growth of cancer. This offers a striking illustration of the substantial role that environmental variables may play in the development and spread of cancer, underscoring the significance of strict laws and public health efforts to reduce exposure [43], [65], [66].

Table 2. Presents a concise overview of the relationship between arsenic exposure and the incidence of various cancers, underscoring the critical importance of stringent environmental safeguards. This table serves as a stark warning of the health risks posed by arsenic contamination.

Cancer Type	Associated Risk due to Arsenic Exposure	References
Skin Cancer	High	[67]
Lung Cancer	Moderate to High	[68]
Bladder Cancer	High	[69]
Liver Cancer	Moderate	[70]

In the field of cancer therapy, several pharmacological types are essential in combating cancer [71]. Chemotherapeutic agents such as alkylating agents and topoisomerase inhibitors are

frequently employed in the clinical management of cancer. These agents obstruct the proliferation of cancerous cells by disrupting the processes of DNA replication and repair. Radiation therapy, another cornerstone of cancer treatment, utilizes ionizing radiation to specifically target and eliminate malignant cells while minimizing damage to adjacent normal tissues [72]. Hormonal therapies are particularly effective in treating hormone-dependent cancers, such as breast and prostate cancers, by mitigating the effects of hormones that facilitate tumor growth [73], [74]. Moreover, targeted therapies, including Retinoids, Barbital, Genistein, Anti-EGFR Agents, TGF, TNF, E2F, and Bcl-2, have transformed cancer treatment by selectively targeting key molecular pathways critical for the survival and proliferation of cancer cells. These therapeutic approaches are tailored based on the unique molecular characteristics of a patient's tumor, enabling more personalized and effective treatment strategies.

Table 3. Provides a concise reference for understanding these treatments' therapeutic features and indications by categorizing anti-cancer therapies based on their mechanisms of action and common clinical uses.

Drug Class	Mechanism of Action	Common Uses	References
Topoisomerase Inhibitors	Interfere with DNA replication and repair	Various cancers	[75]
Alkylating Agents	Induce DNA damage	Hematological and solid tumors	[76]
Radiation Therapy	Destroys cancer cells via ionizing radiation	Various cancers	[77]
Hormonal Therapies	Block hormone activity	Breast, prostate, and other hormone-sensitive cancers	[78], [79]
Targeted Therapies	Precisely target molecular pathways	Specific cancer types based on molecular characteristics	[80]

The imperative of cancer prevention cannot be overstated, with a broad spectrum of pharmacological agents and mechanisms under exploration for this purpose. The role of epigenetic modifiers in cancer prevention emerges as particularly significant, as these agents alter gene expression without modifying the DNA sequence itself. By modulating aberrant genomic activities, epigenetic modifiers hold promise in either halting the progression of cancer or averting its onset [81]. Also, the strategic targeting of vascular endothelial growth factor (VEGF) as a preventative approach seeks to inhibit angiogenesis—the formation of new

blood vessels that supply tumors with nutrients and oxygen. This method has shown promise in curtailing the initiation and dissemination of cancer [82].

A variety of chemo-preventive drugs, including COX-2 inhibitors, Retinoids, HDAC inhibitors, and kinase inhibitors, each provide a special method of lowering the risk of cancer. Because they inhibit cyclooxygenase-2, COX-2 inhibitors are essential in reducing chronic inflammation, which is strongly associated with the development of cancer. Retinoids, which are vitamin A derivatives, exhibit their chemo-preventive properties through the stimulation of cellular differentiation and control of cell development, which in turn inhibits the formation of potentially cancerous cells [83]. On the other side, HDAC inhibitors work on histone deacetylases to affect how genes are epigenetically regulated and to restore normal cellular function, which is important in preventing the onset of cancer [84]. By blocking the signaling pathways linked to tumor development and metastasis, kinase inhibitors a broad family of drugs that target different kinases offer a potent defense against cancer [85]. Together, these chemo-preventive drugs highlight the possibility of customized approaches to lower cancer risk via targeting certain cellular and molecular drivers of carcinogenesis [86], [87].

Among the many molecular regulators are, barbital, genistein, anti-EGFR medicines, TGF, TNF, E2F, and Bcl-2, each with specific mechanisms and possibilities in the fight against cancer [88], [89]. Retinoids are important prospects for cancer therapy because they show promise in controlling cell proliferation and differentiation [90]. Retinoids are generated from vitamin A. A barbiturate derivative called barbital has demonstrated promise in preventing the growth of cancer cells [90]. One soy isoflavone that has been linked to anti-cancer effects is genistein, which affects several different cellular pathways [91]. Monoclonal antibodies and small compounds that precisely target the epidermal growth factor receptor a key component in many cancers are examples of anti-EGFR therapies [92]. Transforming Growth Factor (TGF) and Tumour Necrosis Factor (TNF) are versatile molecules that may either stimulate or inhibit tumor growth, contingent on the situation [93]. The transcription factor E2F plays a complex role in the regulation of the cell cycle, and its modification can hinder the proliferation of cancer cells [94]. One of the main targets for cancer treatments that try to cause programmed cell death is the anti-apoptotic protein Bcl-2 [95]. The investigation of these compounds demonstrates their potential as essential instruments in the fight against cancer, providing a wide range of strategies to impede the growth and survival of tumors.

3. Mechanisms of Carcinogenesis

Normal, healthy cells can transform into malignant cells through a multifaceted and intricate process termed carcinogenesis [96]. This progression entails several distinct phases, commencing with the initiation phase triggered by exposure to carcinogenic substances capable of inducing DNA damage [97]. Examples of such carcinogens include industrial chemicals, environmental pollutants, dietary components, physical agents like ionizing radiation, and biological agents such as viruses [98]. DNA damage serves as a critical impetus at this initial phase, leading to mutations within crucial genes. These genetic alterations may manifest as point mutations, gene duplications, deletions, or chromosomal rearrangements, affecting genes such as oncogenes, which promote cell growth, and tumor suppressor genes, which inhibit it. The initiation phase, therefore, establishes a foundation for abnormal cellular regulation by introducing genetic modifications.

After commencement, the promotion phase follows, which is characterized by the genetically altered cells proliferating more quickly than their healthy counterparts [99]. Numerous variables, including altered signaling pathways inside cells often triggered by the presence of growth-promoting substances, can be blamed for this increased cell division [100]. The growth of a clonal population of cells known as a lesion or pre-neoplastic lesion is a crucial component of promotion [101]. These cells get a growth edge over rival cells, which enables them to penetrate the tissue around them. They represent the beginning of malignant transformation, even if they are not yet totally cancerous. This is a crucial transition point from started cells to a population that is actively developing and may eventually result in the growth of a tumor.

The latter stages of carcinogenesis, commonly referred to as progression, are a time of continuing evolution for the first cancerous cells, during which they pick up new characteristics that increase their capacity to cause malignancy [102]. The increasing genetic instability inside the cells, which results in the accumulation of new mutations, is one notable characteristic of this period. The condition evolves into a more severe form due to a rise in genetic instability [103], [104]. Cancer cells become more capable of invading surrounding tissues and blood vessels as the tumor grows, which is an important phase in the metastatic process [105]. Metastasis, or the spread of disease to distant locations inside the body, is the hallmark of advanced cancer and a daunting therapeutic challenge. The importance of comprehending and concentrating on this stage in cancer research and therapy is highlighted by the fact that progression in carcinogenesis refers to the period during which cancer cells become more aggressive, invasive, and ultimately life-threatening [102].

As a whole, carcinogenesis is a complicated process that involves initiation, promotion, and advancement, each of which is characterized by unique molecular and cellular processes. Malignancy begins with initiation, which is brought on by carcinogen exposure and causes genetic changes and DNA damage. The fast division of genetically altered cells known as "promotion" results in the development of pre-cancerous lesions [106]–[108]. The advanced stage of carcinogenesis is known as progression, and it is characterized by the emergence of metastasis, accumulating mutations, and invasive potential [109]. A comprehensive understanding of these pathways is crucial for advancing our knowledge of cancer biology and for the development of effective strategies for cancer prevention and treatment.



Fig. 2. Depicts the basic steps of carcinogenesis, such as initiation, promotion, and progression. Initiation refers to genetic changes caused by carcinogens, whereas promotion refers to enhanced cell division among altered cells, which eventually leads to tumor development and progression.

An intricate and complicated interaction of biological events underlies the molecular pathways behind cancer. When a person is exposed to chemical carcinogens, which interfere with basic DNA replication and repair mechanisms, DNA adducts are frequently formed [110]. ROS, which are produced by ionizing radiation, harm DNA and other important biological components [111]. Through the disruption of host cell signaling pathways, biological agents like viruses can promote the formation of tumors. Contrarily, several medications used to treat cancer might cause genetic changes in normally healthy cells, leading to the development of secondary malignancies [112-114].

4. Carcinogenicity Testing and Regulation

To comprehend and control the intricacies of cancer induction, carcinogenicity testing, and regulation are essential components of public health [115]. Cancer is a complex illness brought on by the complex interaction of genetic changes and environmental factors. Uncontrolled cell development characterizes it, resulting in the establishment of aberrant tissue masses or tumors that can invade surrounding tissues and spread to distant body regions via metastasis. In addition to genetic defects, environmental variables also have a big impact on how cancer develops. Among these environmental variables, pharmaceutical and carcinogenic drugs have become significant determinants, raising the risk of cancer by directly destroying DNA or impairing vital cellular functions.

Understanding the molecular processes that cause cancer is crucial. Cell cycle control, apoptosis (planned cell death), and DNA repair mechanisms are all affected by genetic abnormalities that build up inside a cell's DNA [116]. As a result, the damaged cells are more likely to proliferate unchecked. Genetic mutations can happen spontaneously during DNA replication, but being exposed to substances that cause cancer and drugs that have these properties can hasten this process considerably. These substances can obstruct cellular communication or directly damage DNA, which can foster the onset of malignant processes [117].

Various molecular regulators, including barbital, genistein, Retinoids, anti-EGFR medications, TGF, TNF, E2F, and Bcl-2, are examined, exploring their potential implications in cancer management. Retinoids, derived from vitamin A, exhibit promise in cancer therapy by modifying cellular proliferation and differentiation mechanisms. [83]. Barbital: A derivative of barbiturates with the potential to inhibit the growth of cancer cells [118]. One of the soy isoflavones that contributes to its anti-cancer effects is genistein, which affects several cellular pathways [119]. Anti-EGFR drugs have emerged as important elements in treating various types of cancer. These regulators play a significant role across multiple cancer types, besides those mentioned. They're influential in treating colorectal cancer, lung cancer, pancreatic cancer, and head and neck cancers, among others. We explore the multifaceted roles of TGF and TNF, illustrating their context-dependent influence on tumorigenesis. These cytokines play pivotal roles in cellular signaling pathways, modulating various aspects of cell behaviour such as proliferation, differentiation, apoptosis, and immune responses. TGF, for instance, often acts as a tumor suppressor by inhibiting cell growth in healthy cells but can promote tumor progression in later stages by facilitating invasion and metastasis. TNF, on the other hand, has complex effects, capable of inducing apoptosis in tumor cells but also contributing to tumor

growth and inflammation in certain contexts. Understanding the intricate balance and context-specific effects of these cytokines is crucial in deciphering their roles in tumor development and potential therapeutic interventions. [82]. One transcription factor that is essential for controlling the cell cycle, E2F, provides information on how to stop cancer cells from proliferating [94]. Furthermore, anti-apoptotic protein Bcl-2 is a major target for cancer treatments that seek to cause programmed cell death [93]. The analysis of these various drugs highlights their potential as crucial elements in the current effort to fight cancer by providing flexible methods to impede the growth and survival of tumours. In addition, chemo preventive drugs such as Retinoids, COX-2 inhibitors, HDAC inhibitors, and kinase inhibitors are investigated for their potential to stop cancer from starting and spreading [120]. The potential of COX-2 inhibitors to suppress inflammatory processes linked to cancer has drawn interest. Retinoids are attractive candidates for cancer prevention because of their effects on cell proliferation and differentiation [83]. HDAC inhibitors affect gene expression and epigenetic changes, which may slow the growth of tumours [121]. Kinase inhibitors have been shown to be important in reducing the risk of cancer because they target important signalling pathways [85]. This study offers a thorough analysis of these chemo preventive drugs, demonstrating their capacity to obstruct the development of cancer at different phases. On the other hand, a variety of carcinogenic agents are examined in order to identify their complex pathways of cancer start. These agents include radiation, hormones, TPA, arsenic, topoisomerase inhibitors, alkylating chemicals, and hypoxia. Arsenic, with its subtle, long-term effects, and TPA, a powerful tumour promoter, demonstrate the various ways in which chemicals cause and encourage cancer. The complex molecular pathways and cellular mechanisms involved in carcinogenesis are underscored by the genotoxic effects of alkylating agents and the carcinogenic potential of radiation. Hormones and hypoxia, pivotal factors within tumor microenvironments, are investigated as significant drivers of malignancy. Through an exploration of this intricate landscape, this review seeks to offer a thorough examination of carcinogenic testing and the regulatory frameworks implicated in the complex network of cancer initiation. By doing so, it aims to provide valuable insights for the scientific community, regulators, and policymakers, facilitating a deeper comprehension of cancer causation and aiding in the development of more effective strategies for its prevention and treatment. [72-79].

5. Emerging Trends and Challenges

A parallel rise of opportunities and difficulties has occurred as our understanding of the complexities of cancer biology grows. The development of targeted medicines and personalised medicine offers great potential for the improvement of cancer therapy, offering increased efficacy and less toxicity [122]. These treatment approaches are based on precisely customising therapies to the unique genetic and molecular foundations of particular tumours, encouraging a more individualised approach [123][124]. The use of targeted medicines adds a subtle degree of complication, too, since certain therapies may unintentionally have undesirable effects on tissues other than the ones they are intended to treat, increasing the chance of secondary cancers in a way that wasn't anticipated.



Fig. 3. highlights new trends and existing problems in the field, capturing the changing environment of cancer research

Emerging Trends

Precision Oncology Revolution: Precision medicine is gaining traction, altering the cancer treatment landscape. Oncologists can use tumor molecular profiling to discover particular genetic abnormalities that are causing cancer, leading to the creation of targeted medicines. This personalized method improves therapeutic efficacy while reducing side effects [125].

Dominance of Immunotherapy: Immunotherapy has emerged as a game changer in cancer treatment. Immune checkpoint inhibitors, CAR-T cell treatment, and therapeutic vaccinations are producing impressive outcomes. Using the body's immune system to fight cancer has the potential to revolutionize cancer therapy across the board [126].

Revolution in Early Cancer Detection: Early cancer detection remains a high focus. Early diagnosis is being transformed by liquid biopsies, AI-driven image analysis, and novel biomarkers. These technologies have the potential to shift the emphasis from late-stage therapies to early interventions, therefore considerably increasing survival rates [127].

Holistic Cancer Care: Cancer care is progressively shifting towards more holistic, patient-centered strategies. Recognizing that cancer affects the mind and soul as well as the body, healthcare systems include psychosocial support, mental health services, and survivor care in treatment programs [128].

Cancer Prevention and Lifestyle Changes: Public health programs that promote cancer prevention via lifestyle changes are gaining popularity. Initiatives focus on lowering smoking rates, improving diet and nutrition, boosting physical exercise, and promoting cancer-causing viral immunization [129].

Challenges

Environmental Carcinogens: It is still difficult to identify and regulate environmental carcinogens. Pollutants, toxic substances, and occupational risks continue to increase the risk of cancer. To overcome this issue, further study and tougher laws are required.

Immunotherapy Difficulties: While immunotherapy produces impressive benefits, it also has drawbacks like as immune-related side effects and resistance mechanisms. Immunotherapies' safety and efficacy are being optimized by researchers [130].

Health Disparities: Cancer health inequities remain, with impoverished communities experiencing increased cancer incidence, delayed diagnosis, and restricted access to sophisticated therapies. To address these inequities, tailored treatments and increased healthcare access are required [131].

Data Privacy and Ethics: Because cancer research depends significantly on patient data and genetic information, it is critical to protect data privacy and ethical research practises. Finding a happy medium between scientific progress and ethical issues is a constant problem [132].

Patient Empowerment: Giving patients information and involve them in shared decision-making is becoming more popular. Improving outcomes requires ensuring that patients are well-informed and active partners in their treatment [133].

In a larger sense, the battle against cancer is a multifaceted task that necessitates a multifaceted response. It includes not just scientific advances, but also sociological, ethical, and healthcare system concerns. Accepting these trends and addressing the accompanying issues collectively is critical to advance our efforts to effectively prevent, diagnose, and treat cancer on a worldwide scale.

6. Conclusion

Cancer research includes a rigorous assessment of carcinogenic medications and therapies that have a substantial influence on public health. Cancer is a complicated illness caused by a combination of genetic flaws and environmental factors, resulting in uncontrolled cellular proliferation and tumour development Conclusively, this thorough analysis has shed light on the complex and diverse terrain of cancer induction, providing a thorough comprehension of the interactions among carcinogenic agents, anti-cancer medications, and chemo preventive medicines in the context of cancer research and regulation. The intricacy of the molecular pathways and cellular processes that drive malignancy is highlighted by the dissected mechanisms of carcinogenesis involving a variety of agents, including radiation, hormones, TPA, arsenic, topoisomerase inhibitors, alkylating agents, radiation, and hypoxia. This highlights the necessity of ongoing research and surveillance in the prevention of cancer. Regarding treatment, a wide range of molecular regulators, such as Bcl-2, Barbital, Genistein, TGF, TNF, E2F, and Retinoids, show the adaptability and promise of focused therapies that impede the growth and survival of tumours. Chemo preventive drugs such as Retinoids, HDAC inhibitors, kinase inhibitors, and COX-2 inhibitors all work together to prevent cancer while also lowering the risk of the disease, suggesting a potential direction for population-wide approaches. In order to translate this knowledge into evidence-based strategies for cancer prevention, diagnosis, and treatment, researchers, healthcare professionals, and regulatory authorities must work synergistically. In order to translate this knowledge into evidence-based strategies for cancer prevention, diagnosis, and treatment, researchers, healthcare professionals, and regulatory authorities must work synergistically. This review brings us one step closer to a future in which personalised and efficient cancer management is attainable.

Ethical approval: Not applicable.

Data availability: Not applicable.

References

1. Haas OA. Primary Immunodeficiency and Cancer Predisposition Revisited: Embedding Two Closely Related Concepts Into an Integrative Conceptual Framework. Front Immunol. 2019 Feb 12;9:3136.
2. Carbone M, Arron ST, Beutler B, Bononi A, Cavenee W, Cleaver JE, Croce CM, D'Andrea A, Foulkes WD, Gaudino G, Groden JL, Henske EP, Hickson ID, Hwang PM, Kolodner RD, Mak TW, Malkin D, Monnat RJ Jr, Novelli F, Pass HI, Petrini JH, Schmidt LS, Yang H. Tumour predisposition and cancer syndromes as models to study gene-environment interactions. Nat Rev Cancer. 2020;20(9):533-549.
3. Suarez-Torres JD, Alzate JP, Orjuela-Ramirez ME. The NTP Report on Carcinogens: A valuable resource for public health, a challenge for regulatory science. J Appl Toxicol. 2020;40(1):169-175.
4. Migliore L, Coppedè F. Genetic and environmental factors in cancer and neurodegenerative diseases. Mutat Res. 2002;512(2-3):135-53.
5. Hassanpour SH, Dehghani M. Review of cancer from perspective of molecular. Journal of Cancer Research and Practice. 2017;4(4):127-9.
6. Talseth-Palmer B, Scott R. Genetic Variation and its Role in Malignancy. International journal of biomedical science : IJBS. 2011;7:158-71.
7. Phaniendra A, Jestadi DB, Periyasamy L. Free radicals: properties, sources, targets, and their implication in various diseases. Indian J Clin Biochem. 2015;30(1):11-26.
8. Barnes JL, Zubair M, John K, Poirier MC, Martin FL. Carcinogens and DNA damage. Biochem Soc Trans. 2018;46(5):1213-1224.
9. Shams M, Nezhad N, dehghan A, Alidadi H, Paydar M, Mohammadi A, et al. Heavy metals exposure, carcinogenic and non-carcinogenic human health risks assessment of groundwater around mines in Joghatai, Iran. International Journal of Environmental Analytical Chemistry. 2020;102:1-16
10. Khan Z, Bisen PS. Oncoapoptotic signaling and deregulated target genes in cancers: special reference to oral cancer. Biochim Biophys Acta. 2013;1836(1):123-45.
11. Gebel J, Tuppi M, Sänger N, Schumacher B, Dötsch V. DNA Damaged Induced Cell Death in Oocytes. Molecules. 2020;25(23):5714.
12. Surova O, Zhivotovsky B. Various modes of cell death induced by DNA damage. Oncogene. 2013 Aug 15;32(33):3789-97. doi: 10.1038/onc.2012.556. Epub 2012 Dec 3. PMID: 23208502.
13. Aguado J, Gómez-Inclán C, Leeson HC, Lavin MF, Shiloh Y, Wolvetang EJ. The hallmarks of aging in Ataxia-Telangiectasia. Ageing Research Reviews. 2022;79:101653.
14. Dutta S, Mahalanobish S, Saha S, Ghosh S, Sil PC. Natural products: An upcoming therapeutic approach to cancer. Food Chem Toxicol. 2019;128:240-255.
15. Nilsson R, Liu N-A. Nuclear DNA damages generated by reactive oxygen molecules (ROS) under oxidative stress and their relevance to human cancers, including ionizing radiation-induced neoplasia part I: Physical, chemical and molecular biology aspects. Radiation Medicine and Protection. 2020;1(3):140-52.
16. Yuan M, Zhang G, Bai W, Han X, Li C, Bian S. The Role of Bioactive Compounds in Natural Products Extracted from Plants in Cancer Treatment and Their Mechanisms Related to Anticancer Effects. Oxid Med Cell Longev. 2022;2022:1429869.
17. Pathak MP, Pathak K, Saikia R, Gogoi U, Ahmad MZ, Patowary P, Das A. Immunomodulatory effect of mushrooms and their bioactive compounds in cancer: A comprehensive review. Biomed Pharmacother. 2022;149:112901.

18. Kim KW, Roh JK, Wee HJ, Kim C. Cancer Drug Discovery: Science and History: Springer Netherlands; 2016.
19. Bijauliya R, Alok DS, Singh M, Mishra DSB. A comprehensive review on cancer and anticancer herbal drugs. International Journal of Pharmaceutical Sciences and Research. 2017;8:2740-61.
20. Bhandaria M, Ravipati A, Reddy N, Koyyalamudi S. Traditional Ayurvedic medicines: Pathway to develop anti-cancer drugs. Journal of Molecular Pharmaceutics & Organic Process Research. 2015;03.
21. Rácz B, Spengler G. Repurposing Antidepressants and Phenothiazine Antipsychotics as Efflux Pump Inhibitors in Cancer and Infectious Diseases. Antibiotics (Basel). 2023;12(1):137.
22. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, Jemal A, Siegel RL. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022;72(6):524-541.
23. Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263.
24. Testa U, Castelli G, Pelosi E. Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications. Medicines (Basel). 2019;6(3):82.
25. Santagostino SF, Assenmacher CA, Tarrant JC, Adedeji AO, Radaelli E. Mechanisms of Regulated Cell Death: Current Perspectives. Vet Pathol. 2021;58(4):596-623.
26. Zaorsky NG, Zhang Y, Tchelebi LT, Mackley HB, Chinchilli VM, Zacharia BE. Stroke among cancer patients. Nat Commun. 2019;10(1):5172.
27. de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ. Cancer and heart disease: associations and relations. Eur J Heart Fail. 2019;21(12):1515-1525.
28. Mbemi A, Khanna S, Njiki S, Yedjou CG, Tchounwou PB. Impact of Gene-Environment Interactions on Cancer Development. Int J Environ Res Public Health. 2020 Nov 3;17(21):8089. doi: 10.3390/ijerph17218089. PMID: 33153024; PMCID: PMC7662361.
29. Deng F, Zheng X, Sharma I, Dai Y, Wang Y, Kanwar YS. Regulated cell death in cisplatin-induced AKI: relevance of myo-inositol metabolism. Am J Physiol Renal Physiol. 2021;320(4):F578-F595.
30. Yang HC, Wu YH, Yen WC, Liu HY, Hwang TL, Stern A, Chiu DT. The Redox Role of G6PD in Cell Growth, Cell Death, and Cancer. Cells. 2019;8(9):1055.
31. Abstracts of the Environmental Mutagen Society 43rd Annual Meeting. September 8-12, 2012. Bellevue, Washington, USA. Environ Mol Mutagen. 2012;53 Suppl 1:S13-70.
32. Kay J, Thadhani E, Samson L, Engelward B. Inflammation-induced DNA damage, mutations and cancer. DNA Repair (Amst). 2019;83:102673.
33. Schultze E, Collares T, Lucas CG, Seixas FK. Synergistic and additive effects of ATRA in combination with different anti-tumor compounds. Chem Biol Interact. 2018;285:69-75.
34. Xiong M, Hu W, Tan Y, Yu H, Zhang Q, Zhao C, Yi Y, Wang Y, Wu Y, Wu M. Transcription Factor E2F1 Knockout Promotes Mice White Adipose Tissue Browning Through Autophagy Inhibition. Front Physiol. 2021;12:748040.
35. Trosko JE, Chang CC. Factors to consider in the use of stem cells for pharmaceutic drug development and for chemical safety assessment. Toxicology. 2010;270(1):18-34.

36. Bartsch H, Frank N, Gerhäuser C, Owen RW, Berger MR. International Meeting on Cancer Chemoprevention: molecular basis, mechanisms and trials. Eur J Cancer Prev. 1997 Feb;6(1):80-92.
37. Charidemou E, Koufaris C, Louca M, Kirmizis A, Rubio-Tomás T. Histone methylation in pre-cancerous liver diseases and hepatocellular carcinoma: recent overview. Clin Transl Oncol. 2023;25(6):1594-1605.
38. De Flora S, Ferguson L. Overview of mechanisms of cancer chemopreventive agents. Mutation research. 2006;591:8-15.
39. Valavanidis A. Environmental Carcinogenic Substances, Exposure and Risk Assessment for Carcinogenic Potential. Classification and Regulations by International and National Institutions. website: wwwchem-tox-ecotoxorg. 2017;1:1-33.
40. Pisoschi AM, Pop A. The role of antioxidants in the chemistry of oxidative stress: A review. Eur J Med Chem. 2015;97:55-74.
41. Carpenter DO, Bushkin-Bedient S. Exposure to Chemicals and Radiation During Childhood and Risk for Cancer Later in Life. Journal of Adolescent Health. 2013;52(5, Supplement):S21-S9.
42. Mui UN, Haley CT, Tyring SK. Viral Oncology: Molecular Biology and Pathogenesis. J Clin Med. 2017;6(12):111.
43. Andrew AS, Karagas MR, Hamilton JW. Decreased DNA repair gene expression among individuals exposed to arsenic in United States drinking water. Int J Cancer. 2003;104(3):263-8.
44. Matsubara K. [Hepatitis B virus: DNA integration and hepatocellular carcinoma]. Gan To Kagaku Ryoho. 1989;16(3 Pt 2):530-41.
45. Koual M, Tomkiewicz C, Cano-Sancho G, Antignac JP, Bats AS, Coumoul X. Environmental chemicals, breast cancer progression and drug resistance. Environ Health. 2020;19(1):117.
46. Miller EC, Miller JA. Mechanisms of chemical carcinogenesis. Cancer. 1981;47(5 Suppl):1055-64.
47. Dzarlieva-Petrusevska RT, Fusenig NE. Tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced chromosome aberrations in mouse keratinocyte cell lines: a possible genetic mechanism of tumor promotion. Carcinogenesis. 1985;6(10):1447-56.
48. Mohammed Abdul KS, Jayasinghe SS, Chandana EPS, Jayasumana C, De Silva PMCS. Arsenic and human health effects: A review. Environmental Toxicology and Pharmacology. 2015;40(3):828-46.
49. Martinez GR, Loureiro AP, Marques SA, Miyamoto S, Yamaguchi LF, Onuki J, Almeida EA, Garcia CC, Barbosa LF, Medeiros MH, Di Mascio P. Oxidative and alkylating damage in DNA. Mutat Res. 2003;544(2-3):115-27.
50. Burgio E, Piscitelli P, Migliore L. Ionizing Radiation and Human Health: Reviewing Models of Exposure and Mechanisms of Cellular Damage. An Epigenetic Perspective. Int J Environ Res Public Health. 2018;15(9):1971.
51. Gleave M, Goldenberg SL, Bruchovsky N, Rennie P. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer Prostatic Dis. 1998;1(6):289-296.
52. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem. 2009;107(6):1053-62.

53. Nishikawa A, Nagano K, Kojima H, Ogawa K. A comprehensive review of mechanistic insights into formaldehyde-induced nasal cavity carcinogenicity. Regul Toxicol Pharmacol. 2021;123:104937.
54. Spatari G, Allegra A, Carrieri M, Pioggia G, Gangemi S. Epigenetic Effects of Benzene in Hematologic Neoplasms: The Altered Gene Expression. Cancers (Basel). 2021;13(10):2392.
55. Jomova K, Jenisova Z, Feszterova M, Baros S, Liska J, Hudecova D, Rhodes CJ, Valko M. Arsenic: toxicity, oxidative stress and human disease. J Appl Toxicol. 2011;31(2):95-107.
56. Kielhorn J, Melber C, Wahnschaffe U, Aitio A, Mangelsdorf I. Vinyl chloride: still a cause for concern. Environ Health Perspect. 2000;108(7):579-88.
57. Mishra S, Bharagava RN. Toxic and genotoxic effects of hexavalent chromium in environment and its bioremediation strategies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2016;34(1):1-32.
58. Kanwar P, Kumar M, Srivastava S. Investigation of phytoextraction and tolerance capacity of Calotropis procera for the detoxification of hexavalent chromium, nickel, and lead. Environmental Technology & Innovation. 2023;32:103238.
59. Schmiederer M, Knutson E, Muganda P, Albrecht T. Acute exposure of human lung cells to 1,3-butadiene diepoxide results in G1 and G2 cell cycle arrest. Environ Mol Mutagen. 2005;45(4):354-64.
60. Exon JH. A review of the toxicology of acrylamide. J Toxicol Environ Health B Crit Rev. 2006;9(5):397-412. doi:
61. Ifegwu OC, Anyakora C. Polycyclic Aromatic Hydrocarbons: Part I. Exposure. Adv Clin Chem. 2015;72:277-304.
62. Hong YS, Song KH, Chung JY. Health effects of chronic arsenic exposure. J Prev Med Public Health. 2014;47(5):245-52.
63. Yoshida T, Yamauchi H, Fan Sun G. Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicol Appl Pharmacol. 2004;198(3):243-52.
64. Muenyi CS, Ljungman M, States JC. Arsenic Disruption of DNA Damage Responses-Potential Role in Carcinogenesis and Chemotherapy. Biomolecules. 2015;5(4):2184-93.
65. Faita F, Cori L, Bianchi F, Andreassi MG. Arsenic-induced genotoxicity and genetic susceptibility to arsenic-related pathologies. Int J Environ Res Public Health. 2013;10(4):1527-46.
66. Chen H, Li S, Liu J, Diwan BA, Barrett JC, Waalkes MP. Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis. Carcinogenesis. 2004;25(9):1779-86.
67. Surdu S, Fitzgerald EF, Bloom MS, Boscoe FP, Carpenter DO, Haase RF, Gurzau E, Rudnai P, Koppova K, Févotte J, Vahter M, Leonardi G, Goessler W, Kumar R, Fletcher T. Occupational exposure to arsenic and risk of nonmelanoma skin cancer in a multinational European study. Int J Cancer. 2013;133(9):2182-91.
68. Heck JE, Andrew AS, Onega T, Rigas JR, Jackson BP, Karagas MR, Duell EJ. Lung cancer in a U.S. population with low to moderate arsenic exposure. Environ Health Perspect. 2009;117(11):1718-23.

69. Song Y, Jin D, Chen J, Liang W, Liu X. Effects of Arsenic (+3 Oxidation State) Methyltransferase Gene Polymorphisms and Expression on Bladder Cancer: Evidence from a Systematic Review, Meta-analysis and TCGA Dataset. Toxicol Sci. 2020;177(1):27-40.
70. Wang W, Cheng S, Zhang D. Association of inorganic arsenic exposure with liver cancer mortality: A meta-analysis. Environmental Research. 2014;135:120-5.
71. Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52-79.
72. Koka K, Verma A, Dwarakanath BS, Papineni RVL. Technological Advancements in External Beam Radiation Therapy (EBRT): An Indispensable Tool for Cancer Treatment. Cancer Manag Res. 2022;14:1421-1429.
73. Ong S, O'Brien J, Medhurst E, Lawrentschuk N, Murphy D, Azad A. Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer-a narrative review. Transl Androl Urol. 2021;10(10):3918-3930.
74. Desai K, McManus JM, Sharifi N. Hormonal Therapy for Prostate Cancer. Endocr Rev. 2021;42(3):354-373.
75. Xu Y, Her C. Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy. Biomolecules. 2015;5(3):1652-70.
76. Ralhan R, Kaur J. Alkylating agents and cancer therapy. Expert Opin Ther Pat. 2007;17:1061-75.
77. Baskar R, Dai J, Wenlong N, Yeo R, Yeoh KW. Biological response of cancer cells to radiation treatment. Front Mol Biosci. 2014;1:24.
78. Liu WJ, Zhao G, Zhang CY, Yang CQ, Zeng XB, Li J, Zhu K, Zhao SQ, Lu HM, Yin DC, Lin SX. Comparison of the roles of estrogens and androgens in breast cancer and prostate cancer. J Cell Biochem. 2020;121(4):2756-2769.
79. Bayala B, Zoure AA, Baron S, de Joussineau C, Simpore J, Lobaccaro JA. Pharmacological Modulation of Steroid Activity in Hormone-Dependent Breast and Prostate Cancers: Effect of Some Plant Extract Derivatives. Int J Mol Sci. 2020;21(10):3690.
80. Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018;834:188-196.
81. A. P. Feinberg, M. A. Koldobskiy, and A. Göndör, "Epigenetic modulators, modifiers and mediators in cancer aetiology and progression," Nat. Rev. Genet., vol. 17, no. 5, pp. 284–299, 2016, doi: 10.1038/nrg.2016.13.
82. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 2000 Jun;52(2):237-68.
83. Clarke N, Germain P, Altucci L, Gronemeyer H. Retinoids: potential in cancer prevention and therapy. Expert Rev Mol Med. 2004;6(25):1-23.
84. Cunningham F, Elliott J, Lees P. Comparative and Veterinary Pharmacology 2010.
85. Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer with kinase inhibitors. J Clin Invest. 2015;125(5):1780-9.
86. William WN Jr, Heymach JV, Kim ES, Lippman SM. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov. 2009;8(3):213-25.
87. Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET. Molecular cancer prevention: Current status and future directions. CA Cancer J Clin. 2015;65(5):345-83.

88. Silva-Oliveira RJ, Melendez M, Martinho O, Zanon MF, de Souza Viana L, Carvalho AL, Reis RM. AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors. Oncotarget. 2017;8(32):53288-53301.
89. Pützer BM. E2F1 death pathways as targets for cancer therapy. J Cell Mol Med. 2007;11(2):239-51.
90. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis. 2000;21(7):1271-9.
91. Suthar A, Banavalikar M, Biyani M. Pharmacological activities of genistein, an isoflavone from soy (Glycine max): part I-anti-cancer activity. 2001.
92. Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs. 2009;20(10):851-5.
93. Gregory C. Apoptosis in Cancer Pathogenesis and Anti-cancer Therapy: New Perspectives and Opportunities2016.
94. Müller H, Helin K. The E2F transcription factors: key regulators of cell proliferation. Biochim Biophys Acta. 2000;1470(1):M1-12.
95. D'Aguanno S, Del Bufalo D. Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer. Cells. 2020;9(5):1287.
96. Tarin D. Cell and tissue interactions in carcinogenesis and metastasis and their clinical significance. Seminars in Cancer Biology. 2011;21(2):72-82.
97. Basu AK. DNA Damage, Mutagenesis and Cancer. Int J Mol Sci. 2018;19(4):970.
98. Chemical carcinogens: a review of the science and its associated principles. U.S. Interagency Staff Group on Carcinogens. Environ Health Perspect. 1986;67:201-82.
99. Parkinson EK. Defective responses of transformed keratinocytes to terminal differentiation stimuli. Their role in epidermal tumour promotion by phorbol esters and by deep skin wounding. Br J Cancer. 1985;52(4):479-93.
100. Rahman MM, Sarker MT, Alam Tumpa MA, Yamin M, Islam T, Park MN, Islam MR, Rauf A, Sharma R, Cavalu S, Kim B. Exploring the recent trends in perturbing the cellular signaling pathways in cancer by natural products. Front Pharmacol. 2022;13:950109.
101. Devi PU. Basics of carcinogenesis. Health Adm. 2004;17(1):16-24.
102. Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12(1):31-46.
103. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396(6712):643-9.
104. Raptis S, Bapat B. Genetic instability in human tumors. Cancer: Cell Structures, Carcinogens and Genomic Instability. Basel: Birkhäuser Basel; 2006. p. 303-20.
105. Kondo T, Oka T, Sato H, Shinnou Y, Washio K, Takano M, et al. Accumulation of aberrant CpG hypermethylation by Helicobacter pylori infection promotes development and progression of gastric MALT lymphoma. Int J Oncol. 2009;35(3):547-57. doi: 10.3892/ijo_00000366.
106. Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, Longacre M. Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci. 2013 Oct 21;14(10):21087-113.
107. Testa U, Pelosi E, Castelli G. Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. Med Sci (Basel). 2018;6(2):31.

108. Sravani AB, Ghate V, Lewis S. Human papillomavirus infection, cervical cancer and the less explored role of trace elements. Biological Trace Element Research. 2023;201(3):1026-50.
109. Shlyakhtina Y, Moran KL, Portal MM. Genetic and Non-Genetic Mechanisms Underlying Cancer Evolution. Cancers (Basel). 2021;13(6):1380.
110. Stading R, Gastelum G, Chu C, Jiang W, Moorthy B. Molecular mechanisms of pulmonary carcinogenesis by polycyclic aromatic hydrocarbons (PAHs): Implications for human lung cancer. Semin Cancer Biol. 2021;76:3-16.
111. Sahoo BM, Banik BK, Borah P, Jain A. Reactive Oxygen Species (ROS): Key Components in Cancer Therapies. Anticancer Agents Med Chem. 2022;22(2):215-222.
112. Kohan R, Collin A, Guizzardi S, Talamoni N, Picotto G. Reactive oxygen species in cancer: a paradox between pro- and anti-tumour activities. Cancer Chemotherapy and Pharmacology. 2020;86.
113. Kirtonia A, Sethi G, Garg M. The multifaceted role of reactive oxygen species in tumorigenesis. Cell Mol Life Sci. 2020;77(22):4459-4483.
114. Molujin AM, Abbasiliasi S, Nurdin A, Lee PC, Gansau JA, Jawan R. Bacteriocins as Potential Therapeutic Approaches in the Treatment of Various Cancers: A Review of In Vitro Studies. Cancers (Basel). 2022;14(19):4758.
115. Reece AS, Hulse GK. Clinical Epigenomic Explanation of the Epidemiology of Cannabinoid Genotoxicity Manifesting as Transgenerational Teratogenesis, Cancerogenesis and Aging Acceleration. Int J Environ Res Public Health. 2023;20(4):3360.
116. Aziz K, Nowsheen S, Pantelias G, Iliakis G, Gorgoulis VG, Georgakilas AG. Targeting DNA damage and repair: embracing the pharmacological era for successful cancer therapy. Pharmacol Ther. 2012;133(3):334-50.
117. Vassilev A, DePamphilis ML. Links between DNA Replication, Stem Cells and Cancer. Genes (Basel). 2017;8(2):45.
118. Zhang S, Liu M, Yao Y, Yu B, Liu H. Targeting LSD1 for acute myeloid leukemia (AML) treatment. Pharmacol Res. 2021;164:105335.
119. Tuli HS, Tuorkey MJ, Thakral F, Sak K, Kumar M, Sharma AK, Sharma U, Jain A, Aggarwal V, Bishayee A. Molecular Mechanisms of Action of Genistein in Cancer: Recent Advances. Front Pharmacol. 2019;10:1336.
120. Hunsu VO, Facey COB, Fields JZ, Boman BM. Retinoids as Chemo-Preventive and Molecular-Targeted Anti-Cancer Therapies. Int J Mol Sci. 2021 Jul 20;22(14):7731.
121. Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci. 2017;18(7):1414.
122. Hoeben A, Joosten EAJ, van den Beuken-van Everdingen MHJ. Personalized Medicine: Recent Progress in Cancer Therapy. Cancers (Basel). 2021;13(2):242.
123. Min HY, Lee HY. Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022;54(10):1670-1694.
124. Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, Kitui SK, Manyazewal T. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021;9:20503121211034366.
125. Tsimberidou AM, Eggermont AMM, Schilsky RL. Precision Cancer Medicine: The Future Is Now, Only Better. American Society of Clinical Oncology Educational Book. 2014(34):61-9.

126. Utkarsh K, Srivastava N, Kumar S, Khan A, Dagar G, Kumar M, Singh M, Haque S. CAR-T cell therapy: a game-changer in cancer treatment and beyond. Clin Transl Oncol. 2024;26(6):1300-1318.
127. Brito-Rocha T, Constâncio V, Henrique R, Jerónimo C. Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests. Cells. 2023;12(6):935.
128. Cadet T, Davis C, Elks J, Wilson P. A Holistic Model of Care to Support Those Living with and beyond Cancer. Healthcare (Basel). 2016;4(4):88.
129. Kerschbaum E, Nüssler V. Cancer Prevention with Nutrition and Lifestyle. Visc Med. 2019;35(4):204-209.
130. Ventola CL. Cancer Immunotherapy, Part 3: Challenges and Future Trends. P T. 2017;42(8):514-521.
131. Patel MI, Lopez AM, Blackstock W, Reeder-Hayes K, Moushey EA, Phillips J, Tap W. Cancer Disparities and Health Equity: A Policy Statement From the American Society of Clinical Oncology. J Clin Oncol. 2020;38(29):3439-3448.
132. Mathaiyan J, Chandrasekaran A, Davis S. Ethics of genomic research. Perspect Clin Res. 2013 Jan;4(1):100-4. doi: 10.4103/2229-3485.106405. PMID: 23533991; PMCID: PMC3601693.
133. Galletta M, Piazza MF, Meloni SL, Chessa E, Piras I, Arnetz JE, D'Aloja E. Patient Involvement in Shared Decision-Making: Do Patients Rate Physicians and Nurses Differently? Int J Environ Res Public Health. 2022;19(21):14229.